JC
Jon Congleton (Chief Executive Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $9.1M of MLYS (200,000 sh across 6 lots, as filed), executed Nov 11 2025. Data as of Nov 7 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
7
0 buys · 7 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$7.1M
shares × price, as filed
Last traded
Sep 30
Filed Oct 2
Median ADV $38.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $17.3M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
7 filings
Sector per market data · by filing · past 12 months
Most traded names
MLYS
Mineralys Therapeutics, Inc.
MLYS · 0 buys · 11 sells
11 filings
Recent filings
MLYSSALE
Mineralys Therapeutics, Inc.
View filing →
$1.9M75,000 sh × $25.46
Exec Sep 30
Filed Oct 2 · 5:53 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $291K
10,700 sh × $27.24
Exec Jul 13
Filed Jul 15 · 8:58 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $2.0M
75,000 sh across 2 lots
Exec Jun 30
Filed Jun 30 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $422K
15,730 sh × $26.83
Exec Apr 13
Filed Apr 15 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $2.0M
74,547 sh across 2 lots
Exec Mar 31
Filed Apr 2 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $530K
16,236 sh across 2 lots
Exec Jan 12
Filed Jan 13 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $9.1M
200,000 sh across 6 lots
Exec Nov 11 2025
Filed Nov 13 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $578K
13,548 sh × $42.63
Exec Oct 13 2025
Filed Oct 15 2025 · 5:30 PM ET More filings →